Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...

The research also highlights potential avenues for repurposing existing drugs. Researchers found that trimethoprim and sulfamethoxazole, antibiotics used to treat ... funding from Calico Life Sciences ...

Treatment MarketThe global urinary tract infection (UTI) treatment market is poised for consistent growth, with an estimated ...

Companion Animal Specialty Drugs MarketThe global companion animal drugs market, valued at USD 36.7 billion in 2022, is ...

Researchers are re-examining streptothricin, an antibiotic that was first created more than 80 years ago, in hopes of determining whether it might effectively combat drug-resistant superbugs.

In 2019, bacterial antibiotic resistance killed an estimated 4.95 million people worldwide. By targeting the specific genes responsible for resistance to existing drugs, our approach could lead to ...